103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB4450
 
Introduced , by Rep. Jackie Haas
 
SYNOPSIS AS INTRODUCED:

720 ILCS 570/208 from Ch. 56 1/2, par. 1208
 Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.


LRB103 36645 RLC 66754 b


 
 
A BILL FOR
 
HB4450LRB103 36645 RLC 66754 b


1 AN ACT concerning criminal law.

2 Be it enacted by the People of the State of Illinois, 
3represented in the General Assembly:

4 Section 5. The Illinois Controlled Substances Act is 
5amended by changing Section 208 as follows:

6 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
7 Sec. 208. (a) The controlled substances listed in this 
8Section are included in Schedule III.
9 (b) Unless specifically excepted or unless listed in 
10another schedule, any material, compound, mixture, or 
11preparation which contains any quantity of the following 
12substances having a stimulant effect on the central nervous 
13system, including its salts, isomers (whether optical 
14position, or geometric), and salts of such isomers whenever 
15the existence of such salts, isomers, and salts of isomers is 
16possible within the specific chemical designation;
17  (1) Those compounds, mixtures, or preparations in 
18 dosage unit form containing any stimulant substances 
19 listed in Schedule II which compounds, mixtures, or 
20 preparations were listed on August 25, 1971, as excepted 
21 compounds under Title 21, Code of Federal Regulations, 
22 Section 308.32, and any other drug of the quantitative 
23 composition shown in that list for those drugs or which is 
 
 
HB4450- 2 -LRB103 36645 RLC 66754 b


1 the same except that it contains a lesser quantity of 
2 controlled substances;
3  (2) Benzphetamine;
4  (3) Chlorphentermine;
5  (4) Clortermine;
6  (5) Phendimetrazine.
7 (c) Unless specifically excepted or unless listed in 
8another schedule, any material, compound, mixture, or 
9preparation which contains any quantity of the following 
10substances having a potential for abuse associated with a 
11depressant effect on the central nervous system:
12  (1) Any compound, mixture, or preparation containing 
13 amobarbital, secobarbital, pentobarbital or any salt 
14 thereof and one or more other active medicinal ingredients 
15 which are not listed in any schedule;
16  (2) Any suppository dosage form containing 
17 amobarbital, secobarbital, pentobarbital or any salt of 
18 any of these drugs and approved by the Federal Food and 
19 Drug Administration for marketing only as a suppository;
20  (3) Any substance which contains any quantity of a 
21 derivative of barbituric acid, or any salt thereof:
22  (3.1) Aprobarbital;
23  (3.2) Butabarbital (secbutabarbital);
24  (3.3) Butalbital;
25  (3.4) Butobarbital (butethal); 
26  (4) Chlorhexadol;
 
 
HB4450- 3 -LRB103 36645 RLC 66754 b


1  (5) Methyprylon;
2  (6) Sulfondiethylmethane;
3  (7) Sulfonethylmethane;
4  (8) Sulfonmethane;
5  (9) Lysergic acid;
6  (10) Lysergic acid amide;
7  (10.1) Tiletamine or zolazepam or both, or any salt of 
8 either of them.
9 Some trade or other names for a tiletamine-zolazepam

10 combination product: Telazol.

11 Some trade or other names for Tiletamine:

12 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

13 Some trade or other names for zolazepam:

14 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

15 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
16  (11) Any material, compound, mixture or preparation 
17 containing not more than 12.5 milligrams of pentazocine or 
18 any of its salts, per 325 milligrams of aspirin;
19  (12) Any material, compound, mixture or preparation 
20 containing not more than 12.5 milligrams of pentazocine or 
21 any of its salts, per 325 milligrams of acetaminophen;
22  (13) Any material, compound, mixture or preparation 
23 containing not more than 50 milligrams of pentazocine or 
24 any of its salts plus naloxone HCl USP 0.5 milligrams, per 
25 dosage unit;
26  (14) Ketamine;
 
 
HB4450- 4 -LRB103 36645 RLC 66754 b


1  (15) Thiopental; . 
2  (16) Xylazine: (N-2,6-dimethylpheny1)-5,6- 
3 dihydro-4H-1,3 thiazin-2-amine), including its isomers, 
4 esters, ethers, salts, and salts of isomers, esters, and 
5 ethers, whenever the existence of such isomers, esters, 
6 ethers, and salts is possible within the specific chemical 
7 designation. 
8 (d) Nalorphine.
9 (d.5) Buprenorphine. 
10 (e) Unless specifically excepted or unless listed in 
11another schedule, any material, compound, mixture, or 
12preparation containing limited quantities of any of the 
13following narcotic drugs, or their salts calculated as the 
14free anhydrous base or alkaloid, as set forth below:
15  (1) not more than 1.8 grams of codeine per 100 
16 milliliters or not more than 90 milligrams per dosage 
17 unit, with an equal or greater quantity of an isoquinoline 
18 alkaloid of opium;
19  (2) not more than 1.8 grams of codeine per 100 
20 milliliters or not more than 90 milligrams per dosage 
21 unit, with one or more active non-narcotic ingredients in 
22 recognized therapeutic amounts;
23  (3) (blank);
24  (4) (blank);
25  (5) not more than 1.8 grams of dihydrocodeine per 100 
26 milliliters or not more than 90 milligrams per dosage 
 
 
HB4450- 5 -LRB103 36645 RLC 66754 b


1 unit, with one or more active, non-narcotic ingredients in 
2 recognized therapeutic amounts;
3  (6) not more than 300 milligrams of ethylmorphine per 
4 100 milliliters or not more than 15 milligrams per dosage 
5 unit, with one or more active, non-narcotic ingredients in 
6 recognized therapeutic amounts;
7  (7) not more than 500 milligrams of opium per 100 
8 milliliters or per 100 grams, or not more than 25 
9 milligrams per dosage unit, with one or more active, 
10 non-narcotic ingredients in recognized therapeutic 
11 amounts;
12  (8) not more than 50 milligrams of morphine per 100 
13 milliliters or per 100 grams with one or more active, 
14 non-narcotic ingredients in recognized therapeutic 
15 amounts.
16 (f) Anabolic steroids, except the following anabolic 
17steroids that are exempt:
18  (1) Androgyn L.A.;
19  (2) Andro-Estro 90-4;
20  (3) depANDROGYN;
21  (4) DEPO-T.E.;
22  (5) depTESTROGEN;
23  (6) Duomone;
24  (7) DURATESTRIN;
25  (8) DUO-SPAN II;
26  (9) Estratest;
 
 
HB4450- 6 -LRB103 36645 RLC 66754 b


1  (10) Estratest H.S.;
2  (11) PAN ESTRA TEST;
3  (12) Premarin with Methyltestosterone;
4  (13) TEST-ESTRO Cypionates;
5  (14) Testosterone Cyp 50 Estradiol Cyp 2;
6  (15) Testosterone Cypionate-Estradiol Cypionate 
7 injection; and
8  (16) Testosterone Enanthate-Estradiol Valerate 
9 injection.
10 (g) Hallucinogenic substances.
11  (1) Dronabinol (synthetic) in sesame oil and 
12 encapsulated in a soft gelatin capsule in a U.S. Food and 
13 Drug Administration approved product. Some other names for 
14 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- 
15 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or 
16 (-)-delta-9-(trans)-tetrahydrocannabinol.
17  (2) (Reserved).
18 (h) The Department may except by rule any compound, 
19mixture, or preparation containing any stimulant or depressant 
20substance listed in subsection (b) from the application of all 
21or any part of this Act if the compound, mixture, or 
22preparation contains one or more active medicinal ingredients 
23not having a stimulant or depressant effect on the central 
24nervous system, and if the admixtures are included therein in 
25combinations, quantity, proportion, or concentration that 
26vitiate the potential for abuse of the substances which have a 
 
 
HB4450- 7 -LRB103 36645 RLC 66754 b